Condition: Non-erosive Reflux Disease · Sponsor: Braintree Laboratories
The objective of the Treatment Phase of the study is to evaluate the safety and efficacy of 4 weeks of once daily oral administration of BLI5100 low dose, BLI5100 high dose, or placebo in patients with NERD. The objective of the Extension Phase of the study is to evaluate the safety of extended exposure to once daily oral administration of BLI5100 low dose and BLI5100 high dose in patients with NERD.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Research Site 24 | Huntsville, Alabama, United States | — |
| Research Site 132 | Peoria, Arizona, United States | — |
| Research Site 62 | Phoenix, Arizona, United States | — |
| Research Site 27 | Tucson, Arizona, United States | — |
| Research Site 87 | Little Rock, Arkansas, United States | — |
| Research Site 117 | North Little Rock, Arkansas, United States | — |
| Research Site 51 | Arcadia, California, United States | — |
| Research Site 126 | Bakersfield, California, United States | — |
| Research Site 66 | Bell Gardens, California, United States | — |
| Research Site 19 | Canoga Park, California, United States | — |
| Research Site 94 | Chula Vista, California, United States | — |
| Research Site 10 | Huntington Park, California, United States | — |
+ 100 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05587322